Annotation Detail for TEX2
Basic Information
Top
| Chemical ID |
Chemical Name |
Interaction |
Interaction Action |
Publication |
|---|
| C016403 |
2,4-dinitrotoluene |
2,4-dinitrotoluene affects the expression of TEX2 mRNA | affects expression | 21346803
|
| C023514 |
2,6-dinitrotoluene |
2,6-dinitrotoluene affects the expression of TEX2 mRNA | affects expression | 21346803
|
| D015123 |
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide |
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in decreased expression of TEX2 mRNA | decreases expression | 19150397
|
| D016572 |
Cyclosporine |
Cyclosporine results in decreased expression of TEX2 mRNA | decreases expression | 20106945
|
| Disease ID |
Disease Name |
Direct Evidence |
Inference Chemical Name |
Inference Score |
Publication |
|---|
| MESH:D006528 |
Carcinoma, Hepatocellular |
|
2,4-dinitrotoluene |
3.10 | 16705839 |
| MESH:D006528 |
Carcinoma, Hepatocellular |
|
2,6-dinitrotoluene |
3.10 | 16705839 |
| MESH:D002471 |
Cell Transformation, Neoplastic |
|
2,6-dinitrotoluene |
12.70 | 6135515 |
| MESH:D002471 |
Cell Transformation, Neoplastic |
|
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide |
12.70 | 20889678 |
| MESH:D002471 |
Cell Transformation, Neoplastic |
|
Cyclosporine |
12.70 | 12371664 |
| MESH:D002779 |
Cholestasis |
|
Cyclosporine |
3.21 | 19486331 |
| MESH:D003490 |
Cyanosis |
|
2,4-dinitrotoluene |
12.83 | 18551238 |
| MESH:D003490 |
Cyanosis |
|
2,6-dinitrotoluene |
12.83 | 18551238 |
| MESH:D056486 |
Drug-Induced Liver Injury |
|
2,4-dinitrotoluene |
4.16 | 21346803 18551238 |
| MESH:D056486 |
Drug-Induced Liver Injury |
|
2,6-dinitrotoluene |
4.16 | 21346803 18551238 |
| MESH:D004938 |
Esophageal Neoplasms |
|
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide |
2.15 | 20426865 |
| MESH:D005234 |
Fatty Liver |
|
Cyclosporine |
3.28 | 19224547 |
| MESH:D005355 |
Fibrosis |
|
Cyclosporine |
3.70 | 12639820 12168785 |
| MESH:D005885 |
Gingival Hyperplasia |
|
Cyclosporine |
4.85 | 8708960 |
| MESH:D006457 |
Hemoglobinuria, Paroxysmal |
|
Cyclosporine |
5.05 | 15720958 |
| MESH:D006973 |
Hypertension |
|
Cyclosporine |
2.21 | 10903974 |
| MESH:D007638 |
Keratoconjunctivitis Sicca |
|
Cyclosporine |
5.16 | 15604871 |
| MESH:D007674 |
Kidney Diseases |
|
Cyclosporine |
2.54 | 18776723 8314463 10903974 |
| MESH:D007680 |
Kidney Neoplasms |
|
2,4-dinitrotoluene |
14.44 | 16705839 |
| MESH:D007680 |
Kidney Neoplasms |
|
2,6-dinitrotoluene |
14.44 | 16705839 |
| MESH:D007680 |
Kidney Neoplasms |
|
Cyclosporine |
14.44 | 12371664 |
| MESH:D008113 |
Liver Neoplasms |
|
2,6-dinitrotoluene |
2.27 | 7678174 |
| MESH:D008114 |
Liver Neoplasms, Experimental |
|
2,6-dinitrotoluene |
2.77 | 2876786 6135515 2876784 |
| MESH:D008664 |
Metal Metabolism, Inborn Errors |
|
Cyclosporine |
5.51 | 16801185 |
| MESH:D009336 |
Necrosis |
|
2,4-dinitrotoluene |
12.54 | 18551238 |
| MESH:D009336 |
Necrosis |
|
2,6-dinitrotoluene |
12.54 | 18551238 7678174 |
| MESH:D009402 |
Nephrosis, Lipoid |
|
Cyclosporine |
5.16 | 17954296 |
| MESH:D009404 |
Nephrotic Syndrome |
|
Cyclosporine |
3.65 | 19348381 18481113 |
| MESH:D009784 |
Occupational Diseases |
|
2,4-dinitrotoluene |
10.23 | 12819281 16049721 |
| MESH:D009784 |
Occupational Diseases |
|
2,6-dinitrotoluene |
10.23 | 16049721 |
| MESH:D011230 |
Precancerous Conditions |
|
Cyclosporine |
3.59 | 12371664 |
| MESH:D011565 |
Psoriasis |
|
Cyclosporine |
2.33 | 16882103 |
| MESH:D012640 |
Seizures |
|
2,4-dinitrotoluene |
6.74 | 18551238 |
| MESH:D012640 |
Seizures |
|
2,6-dinitrotoluene |
6.74 | 18551238 |
| MESH:D001749 |
Urinary Bladder Neoplasms |
|
2,4-dinitrotoluene |
5.43 | 16049721 |
| MESH:D001749 |
Urinary Bladder Neoplasms |
|
2,6-dinitrotoluene |
5.43 | 16049721 |
| MESH:D014571 |
Urologic Neoplasms |
|
2,4-dinitrotoluene |
14.19 | 10091137 |
| MESH:D014571 |
Urologic Neoplasms |
|
2,6-dinitrotoluene |
14.19 | 10091137 |
| MESH:D014605 |
Uveitis |
|
Cyclosporine |
4.71 | 1336536 |
| MESH:D014985 |
Xerophthalmia |
|
Cyclosporine |
5.16 | 17120751 |
Related Pathway Information